References
- Montserrat E., Rozman C. Chronic lymphocytic leukaemia treatment. Blood Rev. 1993; 7: 164–175
- Catovsky D., Foa R. B-cell chronic lymphocytic leukaemia. Butterworths, London 1990; 73–112
- Rai K. R. Chronic lymphocytic leukemia in the elderly population. Clin. Geriatr. Med. 1997; 13: 245–249
- Rai K. R., Sawitsky A., Cronkite E. P., Chanand A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
- International Workshop on CLL. Chronic lymphocytic leukaemia: proposals for a revised prognostic system. Br. J. Haematol. 1981; 48: 365–367
- Zwiebel J. A., Cheson B. D. Chronic lymphocytic leukemia: Staging and prognostic factors. Semin. Oncol. 1998; 25: 42–59
- Rozman C., Montserrat E. Chronic lymphocytic leukemia: an update of current treatment approaches. Hematology 1997; 2: 1–9
- Dighiero G., Maloum K., Desablens B., Cazin B., Navarro M., Leblay R., Leporrier M., Janber J., Lepen G., Dreyfus B., Binet J-L., Travade P. Chlorambucil in indolent chronic lymphocytic leukemia. N. Engl. J. Med. 1998; 338: 1506–1514
- Johnson C., Smith A. G., Loffler H., Osby E., Juliusson G., Emmerich B., Wyld P. J., Hiddemann W., The French Cooperative Group on CLL. Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432–1438
- Robak T., Błasiłska-Morawiec M., Błołski J. Z., Krykowski E., Dmoszyłska A., Skotnicki A. B., Konopka L., Hellmann A., Kuratowska Z., Urasiłski I., Kotlarek-Haus S., Maj S. 2-Chlorodeoxyadenosine (2-CdA) and prednisone (P) versus chlorambucil (Ch1) and prednisone as a first line therapy in B-cell chronic lymphocytic leukemia. Blood 1997; 90: 530a, Suppl. 1 (abstr. 2361)
- Baker A. M. The management of leukemia in elderly. Bailliere's Clin Haematol. 1987; 1: 427–448
- Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia. Recommendations of the National Cancer Institute Sponsored Working Group. Am. J. Hematol. 1988; 29: 152–163
- Rai K. R., Savitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
- Kazimierczuk Z., Cottam H. B., Ravanliar G. R., Robins R. K. Synthesis of 2′-deoxytubercidin, 2′-deoxyade-nosin and related 2′-deoxynucleosides via a novel direct ste-reospecific serum salt glycosylation procedure. J. Am. Chem. Soc. 1984; 106: 6379–6382
- Oken M. M., Crech R. H., Tormey D. C., Horton J., Davis T. E., Mc Fadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649–655
- Binet J. L., For The French Cooperative Group on CLL. When and how to treat elderly patients with chronic lymphocytic leukemia (CLL). Hematol. Oncol. 1993; 11: 38, Supl. 1
- Bastion Y., Blay J. Y., Divine Brice M., Bordessoule D., Sebban C., Blanc M., Tilly H., Lederlin P., Deconinck E., Salles B., Dumontet C., Briere J., Coiffer B. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival - A Groupe d'Etude des Lymphomas de l'Adults Study on 453 patients older than 69 years. J. Clin. Oncol. 1997; 15: 2945–2953